Table 2.

Characteristics of N. gonorrhoeae vaccines investigated in the models reviewed.

Vaccine characteristics/efficacies	Definition	Reference
Efficacy in protecting against infection*	The percentage reduction in the risk of acquisition of infection among vaccinated individuals	[25–33]
Efficacy in reducing transmission*	The percentage reduction in the risk of transmission of infection by vaccinated individuals with breakthrough infection	[27,29,32]
Efficacy in reducing symptoms	The degree to which the vaccine reduces the development of symptoms in vaccinated individuals with breakthrough infection	[27,31,32]
Efficacy in reducing duration of infection	A partially protective vaccine reduces the duration of infection	[29]

^*Some studies considered per-partnership efficacy [25,27,28,30] and others per-act efficacy [32], while in others this is not mentioned [26,29,31,33]. For a given per-partnership efficacy, the equivalent value for per-act efficacy is typically higher.